CHICAGO – Sophia Genetics on Friday executed an initial public offering, from which it expects to raise approximately $234 million in gross proceeds before underwriting discounts, commissions, and other expenses. The Swiss-American bioinformatics company expects the IPO to close July 27.
Sophia, which has twin headquarters in Saint-Sulpice, Switzerland and Boston, is selling 13 million common shares at $18 each. The stock is trading on the Nasdaq Global Select Market under the ticker symbol SOPH.
J.P. Morgan, Morgan Stanley, Cowen, and Credit Suisse are serving as joint bookrunning managers for the IPO.